After a busy first day featuring headlines from a who's who of leading biopharma companies, the J.P. | The J.P. Morgan ...
Pill versions of the successful GLP1 drugs from Novo Nordisk and Eli Lilly will likely be on the market in 2026’s first half.
First dose-expansion patient successfully received SB-007 SB-007 addresses the root cause of Stargardt disease with the potential to treat patients across all ABCA4 mutations SB-007 granted FDA ...
TrumpRx is supposed to launch in early 2026. Here's what we know about how buying medicine through the site to get discounts ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
Daiichi Sankyo &AstraZeneca’s Enhertu approved in China as first HER2 directed medicine for patients with HER2 low or HER2 ultralow metastatic breast cancer ...
The U.S. Food and Drug Administration (FDA) said the safety risks associated with Andexxa now outweigh its benefits, prompting AstraZeneca Plc (NASDAQ: AZN) to seek a voluntary withdrawal of the ...
Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...
Kinney Drugs is opening appointments and walk-ins for eligible people to get their second dose of the COVID-19 vaccine. The dosage is recommended for those aged 65 and older, as well as people who are ...
AstraZeneca showcases three new pioneering drugs at major cancer convention in Berlin. AstraZeneca is enjoying a banner year, averaging a successful phase-three readout every month. The chief ...
WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback